200 related articles for article (PubMed ID: 24587330)
1. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.
Bernardo BC; Gao XM; Tham YK; Kiriazis H; Winbanks CE; Ooi JY; Boey EJ; Obad S; Kauppinen S; Gregorevic P; Du XJ; Lin RC; McMullen JR
PLoS One; 2014; 9(2):e90337. PubMed ID: 24587330
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.
Bernardo BC; Ooi JY; Matsumoto A; Tham YK; Singla S; Kiriazis H; Patterson NL; Sadoshima J; Obad S; Lin RC; McMullen JR
J Physiol; 2016 Oct; 594(20):5959-5974. PubMed ID: 27270487
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function.
Bernardo BC; Yildiz GS; Kiriazis H; Harmawan CA; Tai CMK; Ritchie RH; McMullen JR
Cells; 2022 Oct; 11(19):. PubMed ID: 36231079
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy.
Bernardo BC; Nguyen SS; Winbanks CE; Gao XM; Boey EJ; Tham YK; Kiriazis H; Ooi JY; Porrello ER; Igoor S; Thomas CJ; Gregorevic P; Lin RC; Du XJ; McMullen JR
FASEB J; 2014 Dec; 28(12):5097-110. PubMed ID: 25145628
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload.
Bernardo BC; Nguyen SS; Gao XM; Tham YK; Ooi JY; Patterson NL; Kiriazis H; Su Y; Thomas CJ; Lin RC; Du XJ; McMullen JR
Sci Rep; 2016 Mar; 6():22442. PubMed ID: 26928825
[TBL] [Abstract][Full Text] [Related]
7. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases.
Ooi JYY; Bernardo BC; Singla S; Patterson NL; Lin RCY; McMullen JR
RNA Biol; 2017 May; 14(5):500-513. PubMed ID: 27124358
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.
Karakikes I; Chaanine AH; Kang S; Mukete BN; Jeong D; Zhang S; Hajjar RJ; Lebeche D
J Am Heart Assoc; 2013 Apr; 2(2):e000078. PubMed ID: 23612897
[TBL] [Abstract][Full Text] [Related]
9. Cardioprotective effects of miR-34a silencing in a rat model of doxorubicin toxicity.
Piegari E; Cozzolino A; Ciuffreda LP; Cappetta D; De Angelis A; Urbanek K; Rossi F; Berrino L
Sci Rep; 2020 Jul; 10(1):12250. PubMed ID: 32704131
[TBL] [Abstract][Full Text] [Related]
10. AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction.
Hinkel R; Batkai S; Bähr A; Bozoglu T; Straub S; Borchert T; Viereck J; Howe A; Hornaschewitz N; Oberberger L; Jurisch V; Kozlik-Feldmann R; Freudenthal F; Ziegler T; Weber C; Sperandio M; Engelhardt S; Laugwitz KL; Moretti A; Klymiuk N; Thum T; Kupatt C
J Am Coll Cardiol; 2021 Jun; 77(23):2923-2935. PubMed ID: 34112319
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Silencing of MicroRNA-152 Prevents Pressure Overload-Induced Heart Failure.
LaRocca TJ; Seeger T; Prado M; Perea-Gil I; Neofytou E; Mecham BH; Ameen M; Chang ACY; Pandey G; Wu JC; Karakikes I
Circ Heart Fail; 2020 Mar; 13(3):e006298. PubMed ID: 32160771
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease.
Martinez EC; Lilyanna S; Wang P; Vardy LA; Jiang X; Armugam A; Jeyaseelan K; Richards AM
J Mol Cell Cardiol; 2017 Nov; 112():27-39. PubMed ID: 28865712
[TBL] [Abstract][Full Text] [Related]
13. Meox1 accelerates myocardial hypertrophic decompensation through Gata4.
Lu D; Wang J; Li J; Guan F; Zhang X; Dong W; Liu N; Gao S; Zhang L
Cardiovasc Res; 2018 Feb; 114(2):300-311. PubMed ID: 29155983
[TBL] [Abstract][Full Text] [Related]
14. Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload.
Beetz N; Rommel C; Schnick T; Neumann E; Lother A; Monroy-Ordonez EB; Zeeb M; Preissl S; Gilsbach R; Melchior-Becker A; Rylski B; Stoll M; Schaefer L; Beyersdorf F; Stiller B; Hein L
J Mol Cell Cardiol; 2016 Dec; 101():145-155. PubMed ID: 27789290
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of miR-199a-3p in a murine hypertrophic cardiomyopathy (HCM) model attenuates fibrotic remodeling.
Zalivina I; Barwari T; Yin X; Langley SR; Barallobre-Barreiro J; Wakimoto H; Zampetaki A; Mayr M; Avkiran M; Eminaga S
J Mol Cell Cardiol Plus; 2023 Dec; 6():100056. PubMed ID: 38143961
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy.
Roncarati R; Viviani Anselmi C; Losi MA; Papa L; Cavarretta E; Da Costa Martins P; Contaldi C; Saccani Jotti G; Franzone A; Galastri L; Latronico MV; Imbriaco M; Esposito G; De Windt L; Betocchi S; Condorelli G
J Am Coll Cardiol; 2014 Mar; 63(9):920-7. PubMed ID: 24161319
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
18. Moderate Loss of the Extracellular Matrix Proteoglycan Lumican Attenuates Cardiac Fibrosis in Mice Subjected to Pressure Overload.
Mohammadzadeh N; Melleby AO; Palmero S; Sjaastad I; Chakravarti S; Engebretsen KVT; Christensen G; Lunde IG; Tønnessen T
Cardiology; 2020; 145(3):187-198. PubMed ID: 31968347
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-150 Inhibits the Activation of Cardiac Fibroblasts by Regulating c-Myb.
Deng P; Chen L; Liu Z; Ye P; Wang S; Wu J; Yao Y; Sun Y; Huang X; Ren L; Zhang A; Wang K; Wu C; Yue Z; Xu X; Chen M
Cell Physiol Biochem; 2016; 38(6):2103-22. PubMed ID: 27184887
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Karam S; Margaria JP; Bourcier A; Mika D; Varin A; Bedioune I; Lindner M; Bouadjel K; Dessillons M; Gaudin F; Lefebvre F; Mateo P; Lechène P; Gomez S; Domergue V; Robert P; Coquard C; Algalarrondo V; Samuel JL; Michel JB; Charpentier F; Ghigo A; Hirsch E; Fischmeister R; Leroy J; Vandecasteele G
Circulation; 2020 Jul; 142(2):161-174. PubMed ID: 32264695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
